GT
MRNA icon

Greenleaf Trust’s Moderna MRNA Stock Holding History

Greenleaf Trust’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$288K Buy
+5,676
New +$265K ﹤0.01% 667
2025
Q1 		– Sell
-5,244
Closed -$218K – 819
2024
Q4 		$218K Buy
5,244
+1,739
+50% +$83.1K ﹤0.01% 757
2024
Q3 		$234K Sell
3,505
-1,894
-35% -$174K ﹤0.01% 746
2024
Q2 		$641K Buy
5,399
+2,146
+66% +$272K 0.01% 413
2024
Q1 		$347K Buy
3,253
+953
+41% +$96.1K ﹤0.01% 567
2023
Q4 		$229K Sell
2,300
-485
-17% -$40.8K ﹤0.01% 679
2023
Q3 		$288K Sell
2,785
-307
-10% -$34.2K ﹤0.01% 589
2023
Q2 		$376K Sell
3,092
-425
-12% -$56.7K ﹤0.01% 529
2023
Q1 		$540K Sell
3,517
-1,547
-31% -$255K 0.01% 428
2022
Q4 		$910K Buy
5,064
+2,251
+80% +$368K 0.01% 282
2022
Q3 		$333K Sell
2,813
-217
-7% -$32.9K ﹤0.01% 505
2022
Q2 		$433K Buy
3,030
+111
+4% +$15.9K 0.01% 448
2022
Q1 		$503K Buy
2,919
+192
+7% +$32.3K 0.01% 416
2021
Q4 		$693K Sell
2,727
-741
-21% -$217K 0.01% 331
2021
Q3 		$1.33M Buy
+3,468
New +$1.28M 0.02% 178

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Greenleaf Trust's MRNA Position: Q1 2026 in Review

Greenleaf Trust opened a new position in Moderna (MRNA) in Q1 2026: 5,676 shares worth $288K. The stake represents ﹤0.01% of the portfolio and ranks #667 among its holdings. This is a return to the name: Greenleaf Trust previously reported a position in MRNA as recently as Q4 2024.

Greenleaf Trust first reported a position in MRNA in Q3 2021 and has held it in 15 quarters since. The position peaked at $1.33M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Greenleaf Trust held 5,676 shares of Moderna worth $288K as of Q1 2026.
  • Moderna was a new Greenleaf Trust position in Q1 2026.
  • Moderna made up ﹤0.01% of Greenleaf Trust's portfolio in Q1 2026, its #667 holding.
  • Greenleaf Trust first reported a position in Moderna in Q3 2021 and has held it in 15 quarters since.
  • Greenleaf Trust's Moderna position peaked at $1.33M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Greenleaf Trust's 13F filing for Q1 2026, filed 27 Apr 2026.